Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRMT5 siRNA is a small interfering RNA (siRNA) designed to silence the expression of Protein Arginine Methyltransferase 5 (PRMT5). PRMT5 is a type II arginine methyltransferase that plays a critical role in oncogenic and inflammatory signaling, primarily through the PI3K-Akt pathway. In the context of non-small cell lung cancer (NSCLC), PRMT5 is often upregulated, particularly in cells exposed to cigarette smoke and those that have developed resistance to EGFR tyrosine kinase inhibitors (TKIs) like osimertinib. By knocking down PRMT5, this siRNA aims to suppress the surge of pro-inflammatory cytokines such as IL-8, TNF-α, and IL-1β, thereby potentially restoring sensitivity to EGFR-TKIs and inhibiting tumor progression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prmt5 siRNA.